Huons Meditech, the medical device affiliate of Huons Group, said it launched IMPO88 Plus, an upgraded model of its earlier erectile dysfunction device IMPO88.

In addition to treating erectile dysfunction, the new device is now approved for chronic prostatitis and both inflammatory and non-inflammatory CP/CPPS indications.

While low-intensity shockwave therapy has traditionally been used for erectile dysfunction in urology clinics, recent studies have shown its effectiveness in alleviating symptoms of non-inflammatory CP/CPPS.

Building on this research, Huons Meditech stressed it has demonstrated that IMPO88 Plus can effectively treat a broader range of urological conditions beyond erectile dysfunction.

According to the company, preclinical data showed the device significantly reduced inflammation levels in patients with chronic prostatitis and pelvic pain syndrome by suppressing inflammasomes—key cellular drivers of inflammation—without the use of antibiotics.

The new model also enhances user convenience, offering features such as a dedicated treatment chair.

“With IMPO88 Plus, we aim to offer a faster and more effective treatment alternative for patients who previously relied on medication,” Huons Meditech CEO Lee Jin-suk said. “The device provides a viable option not only for patients with limited response to antibiotics but also for clinicians seeking non-pharmacological interventions.”

In an effort to raise awareness of its urology-focused portfolio, Huons Meditech is ramping up its marketing activities through exhibitions and clinical seminars.

The company plans to host the “CP/CPPS Treatment Symposium” at Seoul Dragon City Hotel on June 28, where experts will share insights on treatment strategies for chronic prostatitis, pelvic pain syndrome, erectile dysfunction, and endoscope disinfection practices.